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1. Introduction 
In mammalian cells, DNA can be modified by methylation of cytosine residues in CpG 
dinucleotides, and the N-terminal tails of histone proteins are subject to a wide range of 
different modifications, including acetylation, methylation, phosphorylation and 
ubiquitylation. All of these chemical changes have a substantial influence on chromatin 
structure and gene expression. These epigenetic modification patterns can be regarded as 
heritable marks over many cell generations. Importantly, patterns and levels of DNA 
methylation and histone acetylation/deacetylation are profoundly altered in human 
cancers. Inhibitors of DNA methytransferases (DNMTs) and histone deacetylases (HDACs) 
have been shown to inhibit tumor growth by reactivating epigenetically silenced tumor 
suppressor genes. Although DNA methylation and histone deacetylation are carried out by 
different chemical reactions and require different sets of enzymes, it seems that there is a 
biological relationship between the two systems in modulating gene repression 
programming. Accumulating evidence also suggests that this epigenetic cross-talk may be 
involved in gene transcription and aberrant gene silencing in tumors. Thus, combined 
therapy with both DNMT and HDAC inhibitors can be a promising approach for cancer 
treatment. 
2. Epigenetic gene silencing through DNA methylation and histone 
deacetylation 
2.1 DNA methylation in regulating gene transcription 
DNA methylation is a covalent chemical modification of DNA occurring at cytosine residues 
in CpG dinucleotides. Approximately 70–80% of cytosine in CpG dyads is methylated on 
both strands in human somatic cells(Chen & Riggs, 2011). DNA methylation is a stable 
epigenetic mark that is linked to the maintenance of chromatin in a silent state, therefore 
regulating chromatin structure and gene expression involved in processes such as X 
chromosome inactivation, genomic imprinting, embryogenesis, gametogenesis, and 
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silencing of repetitive DNA elements. Deregulation of DNA methylation directly affects 
mammalian development and development of cancer (Gopalakrishnan et al., 2008).  
The mammalian DNA methyltransferases (DNMTs) are enzymes that catalyze the transfer 
of a methyl group from S-adenosyl-L-methionine to cytosine. Among the three 
enzymatically active DNMTs, DNMT1 is thought to function as the major maintenance 
methyltransferase(Chen & Riggs, 2011). This enzyme maintains DNA methylation at hemi-
methylated DNA after DNA replication (Pradhan et al., 1999), and it is responsible for 
copying pre-existing methylation patterns to the newly synthesized strand (Chen & Li, 
2004). DNMT3A and DNMT3B are de novo methyltransferases active on unmethylated DNA. 
Both of them are responsible for establishing new DNA methylation patterns during early 
development (Okano et al., 1999) as well as maintaining these patterns during mitosis (Chen 
et al., 2003). DNMT3L is homologous to DNMT3A and DNMT3B within the N-terminal 
regulatory region and is highly expressed in germ cells. Although catalytically inactive, 
DNMT3L regulates DNMT3A and DNMT3B by stimulating their catalytic activity (Chen et 
al., 2011). 
Our knowledge about the function of DNA methylation in mammals comes mainly from 
DNMTs transgenic mice studies(Chen & Li, 2004). Studies of the zygotic functions of DNMTs 
have shown that the establishment of embryonic methylation patterns requires both de novo 
and maintenance methyltransferase activities, and that the maintenance of DNA methylation 
above a threshold level is essential for embryonic development (Lei et al., 1996). Complete 
elimination of DNMT1 function results in embryonic lethality around E9.5, with extensive loss 
of global DNA methylation (Li et al., 1992). DNMT3B is also essential for embryogenesis. 
DNMT3B-deficient embryos show growth impairment and multiple developmental defects 
after E9.5 and die after E12.5. DNMT3A mutant mice die around 4 weeks of age. 
DNMT3A/DNMT3B-double knockout embryos die around E9.5, similar to DNMT1-null 
mutants (Okano et al., 1999). Loss of DNA methylation does not affect ES proliferation and 
viability, and the effect of demethylation only becomes apparent during or after gastrulation 
when the pluripotent embryonic cells begin to differentiate (Li et al., 1992,Okano et al., 1999). 
Conditional disruption of DNMT1 in mouse embryonic fibroblasts (MEFs) results in severe 
demethylation and cell death, and DNMT3B deficient MEFs show moderate demethylation, 
chromosomal instability, and abnormal proliferation (Jackson-Grusby et al., 2001,Farthing et 
al., 2008,Dodge et al., 2005). These findings suggest that DNA methylation is essential for 
cellular differentiation and  normal functioning of differentiated cells.  
Development: In mammals, DNA methylation patterns undergo dramatic changes during 
early development. During preimplantation development, both paternal and  maternal 
genomes undergo a wave of demethylation, which erases the methylation marks inherited 
from the gametes. Within 3-6 hours after fertilization, the maternal genome is rapidly 
methylated through de novo DNA methylation, while the paternal genome is actively 
demethylated before the first replication event occurs (Mayer et al., 2000,Oswald et al., 
2000). This is followed in the maternal genome by a loss of DNA methylation gradually over 
several DNA replication cycles (Mayer et al., 2000,Rougier et al., 1998). Replication-
dependent demethylation is caused by the exclusion of maintenance methyltransferase 
DNMT1 from the nucleus of embryos (Carlson et al., 1992,Cardoso & Leonhardt, 1999). As a 
result, maternal and parental genomes become almost equally low in DNA methylation by 
the eight cell stage of development (Mayer et al., 2000). At morula stage, there is an increase 
www.intechopen.com
 
DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer 229 
in de novo methylation. This methylation occurs through the activity of de novo 
methyltransferases DNMT3A and 3B (Okano et al., 1999). Consistent with these data, 
DNMT1-deficient or DNMT3A/DNMT3B-double mutant ES cells show severe 
differentiation defects (Tucker et al., 1996). 
Genomic imprinting: Another developmental stage that exhibits substantial de novo DNA 
methylation in mammals is gametogenesis. DNA methylation in both male and female germ 
cells plays a critical role in the establishment of genomic imprinting. Genomic imprinting is 
an epigenetic process that marks alleles according to their parental origin and results in 
monoallelic expression of a small subset of genes (Reik & Walter, 2001). Genetic studies 
demonstrate that DNMT3A and DNMT3L are essential for setting up DNA methylation 
imprints in germ cells (Kaneda et al., 2004,Bourc'his et al., 2001). Although DNMT3L has no 
enzymatic activity, it has been shown to interact with DNMT3A and stimulate its activity 
(Suetake et al., 2004). Active transcription across imprinting control regions also appears to 
be required for the establishment of DNA methylation imprints in female germ cells 
(Chotalia et al., 2009). It is possible that the removal of H3K4 methylation and active 
transcription at imprinted loci create or maintain a chromatin state that facilitates access of 
the DNMT3A-DNMT3L complex to these loci (Ooi et al., 2007). 
Differentiation: Differentiation is an epigenetic process associated with selective temporal 
activation of lineage-specific genes and regulated silencing of pluripotency genes. 
Pluripotency genes are those that are important for maintaining the unrestricted 
developmental potential of the early embryo and ES cells. Undifferentiated ES cells do not 
show global differences in DNA methylation levels compared to somatic cells (Mohn et al., 
2008). However, changes in DNA methylation at promoter regions were observed (Meissner 
et al., 2008). Among those promoter regions that gain DNA methylation upon differentiation 
of ES cells in culture are pluripotent genes and germ line-specific genes (Farthing et al., 
2008,Mohn et al., 2008). De novo DNA methylation and silencing of the pluripotency genes 
contributes to loss of pluripotency in differentiated cells (Farthing et al., 2008). Oct4 and 
Nanog are two such genes which are essential for pluripotency and early development and 
become methylated after differentiation (Hattori et al., 2004,Hattori et al., 2007,You et al., 
2011). Thus, de novo methylation at promoter regions during cellular differentiation may in 
part control the loss of pluripotency by silencing stem cell-specific genes. 
Once cells have passed through the early embryonic stage, differentiation toward a specific 
lineage pathway occurs. These somatic tissues then contain specific gene expression patterns 
unique for that terminally differentiated cell type. Although DNMT1 is dispensable for ES cell 
maintenance, it is required for maintaining the somatic progenitor state through cell divisions. 
Depletion of the maintenance DNA methyltransferase DNMT1 in epidermal progenitors leads 
to premature differentiation. Genome-wide DNA methylation analysis showed that some 
epidermal differentiation gene promoters were methylated in self-renewing progenitor cells 
but were subsequently demethylated during differentiation (Sen et al., 2010). The correlation 
between gene expression and DNA methylation was investigated in diverse tissues and 
suggests that DNA methylation is critical for regulating the expression of some tissue specific 
genes (Shen et al., 2007,Illingworth et al., 2008). In the case of neuronal development, this 
methylation involves DNMT3A, which is expressed in postnatal neural stem cells and is 
required for neurogenesis (Mohn et al., 2008,Wu et al., 2010).  
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2.2 Histone deacetylation in regulating gene repression 
Histone deacetylases (HDACs) catalyze the removal of acetyl groups from the -amino 
groups of lysine residues. The reversible acetylation of histones and non-histone proteins by 
histone acetyltransferases (HATs) and deacetylases plays a critical role in transcriptional 
regulation and many other cellular processes in eukaryotic cells. Acetylation of histones is 
commonly associated with the transcriptional activation of genes, and is thought to be 
responsible for the formation of a local “open chromatin” structure required for the binding 
of multiple transcription factors (Sterner & Berger, 2000). In contrast, the removal of acetyl 
groups by HDACs frequently accompanies the suppression of gene activity (Ng & Bird, 
2000). However, non-histone protein lysine acetylation plays a diverse role in the regulation 
of all aspects of cellular processes (Glozak et al., 2005).  
Classification: Mammalian HDACs are classified into four classes (I, II, III and IV) based on 
the sequence homology of the yeast histone deacetylases Rpd3 (reduced potassium 
dependency), Hda1 (histone deacetylase1), and Sir2 (silent information regulator 2), 
respectively. Class I HDACs include HDAC1, 2, 3 and 8. Class II HDACs contain HDAC4, 5, 
6, 7, 9 and 10. Class III enzymes, however, require the coenzyme NAD+ as a cofactor. 
HDAC11 belongs to the class IV family (Reviewed in (Yang & Seto, 2008)). Although the 
precise cellular functions of the different HDAC enzymes are still poorly understood, 
evidence suggests that different members of the HDAC family have distinct functions (Cho 
et al., 2005,Foglietti et al., 2006).  
Post-translational modifications: All class I HDACs can be phosphorylated. Phosphorylation of 
HDAC1, 2 and 3 increases deacetylase activities while phosphorylation of HDAC8 inhibits 
deacetylase activity (Sengupta & Seto, 2004). HDAC1 can also be acetylated at the catalytic 
core domain and the C-terminal region, resulting in dramatic reduction of enzymatic 
activity (Qiu et al., 2006). Other modifications of HDAC1 include sumoylation and 
ubiquitylation, which also influence deacetylase activity and protein stability (David et al., 
2002,Oh et al., 2009). Class II HDACs can also be phosphorylated. Phosphorylation does not 
appear to regulate enzymatic activity of class II HDACs; instead, it modulates their 
subcellular localization (Yang & Gregoire, 2005). Class III deacetylases can also be 
phosphorylated. One report showed that phosphorylation of SIRT1 enhances deacetylation 
of p53 (Guo et al., 2010). 
Function and regulation of Class I histone deacetylases: Class I HDACs are ubiquitously 
expressed nuclear proteins. Although they share a high level of sequence homology and 
common substrates, each of the enzymes has a unique role in cell function and cannot 
compensate for the other enzymes’ functions, as deletion of each class I deacetylase leads to 
lethality (Reviewed in (Haberland et al., 2009)). HDACs can be recruited to genes by 
sequence-specific or non sequence-specific DNA-binding factors. Class I deacetylases are 
found to associate with a variety of proteins, such as transcription factors, coactivators, 
corepressors, chromatin remodeling proteins, etc, adding to the complexity of HDACs 
functions (Yang & Seto, 2007). Class I HDACs have been widely implicated in gene 
repression through the hypoacetylation of localized chromatin domains (Strahl & Allis, 
2000). It is a traditionally held view that HDACs are associated with repressed promoters 
and are replaced by coactivators during gene activation (Berger, 2007). However, recent 
advancements in methodology allow studying the localization of HDACs or HATs on a 
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genome-wide scale. The surprising result is that HATs and HDACs are positively correlated 
with gene expression. Levels of HDAC1,2 and 3 are high in active genes and absent from 
silenced genes (Wang et al., 2009). The emerging new model for the role of HDACs is that 
they can counteract histone acetyltransferase to maintain transcription activation within a 
certain level, and they can regulate gene activation as deacetylation resets chromatin for 
subsequent rounds of transcription (Perissi et al., 2010). This model is also supported by 
data that shows HDAC complexes in yeast, Rpd3s, can interact with active chromatin in 
order to prevent transcription initiation from cryptic sites (Li et al., 2007). In some cases, 
HDAC can even function as coactivator (Qiu et al., 2006). Besides  regulation of gene 
transcription, class I HDACs have been shown to also be involved in many other cellular 
processes, especially events that are linked to oncogenesis, such as DNA repair, 
recombination, and replication, cell cycle check point control, and other signaling regulators 
(Spange et al., 2009).  
Class I HDACs, except HDAC8, are often found in multiprotein complexes and their activity 
is regulated through associated complexes (reviewed in (Sengupta & Seto, 2004). HDAC1 
and 2 are found to coexist in at least three evolutionally conserved, distinct protein 
complexes: the Sin3, the CoREST and the NuRD/Mi2 complexes (Grozinger & Schreiber, 
2002,Yang & Seto, 2008). All complexes are recruited to target genes through interactions 
with DNA binding transcription factors (Yang & Seto, 2007). Sin3 contains the conserved 
basic structure of multiple paired amphipathic helix (PAH) domains for protein-protein 
interaction. Mammals have two isoforms, Sin3A and Sin3B, which provide more diverse 
protein complexes for gene regulation. Sin3 does not bind to DNA and has no known 
enzymatic activity of its own. It is suggested that it functions through its ability to interact 
with other proteins. The CoREST complex is a multi-subunit complex containing the lysine 
demethylase LSD1, corepressors CtBP, BHC80, CoREST, HDAC1 and HDAC2 (Lee et al., 
2005,Shi et al., 2003). Thus, this complex is capable of deacetylating as well as demethylating 
nucleosomes. Mi2 belongs to the CHD (chromo-helicase DNA-binding) protein family 
(Woodage et al., 1997). The NuRD complex includes the ATPase/helicase Mi-2, HDAC1 / 
HDAC2, MTA2 (Metastasis-associated) proteins, MBD3 (methyl CpG-binding domain-1), 
RbAp46/48 (Wade et al., 1998,Zhang et al., 1998). Interestingly, recent reports suggest that 
LSD1, a lysine specific demethylase, is also recruited to the NuRD complex through its 
interaction with MTA2 (Wang et al., 2009). Thus, the NuRD complex may regulate gene 
transcription through a combination of deacetylation, demethylation and remodeling. The 
NuRD complex is also part of a larger protein complex, MeCP1 (methyl CpG-binding 
protein 1) complex (Fatemi & Wade, 2006). The MeCP1 complex contains the additional 
component MBD2, a CpG methyl-binding protein. Therefore, NuRD/MeCP1 is targeted to 
methylated CpG sites leading to histone deacetylation and repression at the gene promoter 
(Nan et al., 1998).  
HDAC3 forms a stable complex with nuclear receptor corepressor (N-CoR) and silencing 
mediator of retinoic and thyroid receptors (SMRT) (Wen et al., 2000,Guenther et al., 
2001,Guenther et al., 2000). Both N-CoR and SMRT had been discovered as interacting 
partners of unliganded nuclear receptors, such as TR and RAR and mediators of their 
repressive functions. The interaction between HDAC3 and SMRT/N-CoR seems to be 
essential for HDAC3 deacetylase activity (Guenther et al., 2001).  
HDAC8 was identified as a ubiquitously distributed nuclear enzyme (Hu et al., 2000). 
However, it is also found in the cytosol of smooth muscle cells where it associates with ǂ-
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actin cytoskeleton (Waltregny et al., 2004). A gene deletion study also shows that HDAC8 
plays an important role in skull formation (Haberland et al., 2009). HDAC8 is 
phosphorylated by cyclic AMP-dependent protein kinase A (PKA) in vitro and in vivo. 
Induction of phosphorylation decreases HDAC8's enzymatic activity. Remarkably, 
inhibition of HDAC8 activity by hyperphosphorylation leads to hyperacetylation of histones 
H3 and H4, suggesting that PKA-mediated phosphorylation of HDAC8 plays a central role 
in the overall acetylation status of histones (Lee et al., 2004). 
Functions of Class II deacetylases: class IIa mammalian HDACs mainly function as 
transcriptional corepressor through their deacetylase domain and other repression domains 
(Yang & Gregoire, 2005). Class IIa HDACs share conserved  motifs, such as MEF-2 binding, 
14-3-3 binding and nuclear localization signal at  N-terminal region which are  important for 
the function and regulation of class IIa members (Yang & Gregoire, 2005). These HDACs 
possess intrinsic nuclear import and export signals for nucleo-cytoplasmic trafficking 
(McKinsey et al., 2000). MEF2 and 14-3-3 are major HDAC4 binding partners. While MEF2 
promotes nuclear localization of class IIa HDACs (Miska et al., 1999,Wang & Yang, 2001), 
14-3-3 proteins stimulate cytoplasmic retention (Grozinger & Schreiber, 2000). Class IIa 
HDACs have low deacetylase activity on their own, it is suggested that HDAC3 is needed 
for class IIa HDACs to exert full deacetylase activity (Fischle et al., 2002). 
A class IIb member, HDAC6 possesses two deacetylase domains and a zinc finger motif (Zn-
UBP, ubiquitin carboxyl-terminal hydrolase-like zinc finger) (Seigneurin-Berny et al., 2001). 
HDAC6 deacetylates ǂ-tubulin, Cortactin and HSP90  to regulate cell motility, cilium 
assembly, cell adhesion, the immune synapse, macropinocytosis, maturation of the 
glucocorticoid receptor (GR) and activation of some protein kinases (Yang & Seto, 2008) . 
Depending on its availability in the nucleus, HDAC6 is also able to deacetylate histones 
(Yoshida et al., 2004). In addition to its deacetylase domains, HDAC6 possesses a Zn-UBP 
finger that binds to ubiquitin and is involved in ubiquitin-dependent aggresome formation 
and cellular clearance of misfolded proteins (Rodriguez-Gonzalez et al., 2008,Yang & Seto, 
2008). Both deacetylase and ubiquitin-binding activities of HDAC6 are required for these 
processes. Therefore, HDAC6 regulates various processes in the cytoplasm. Several lines of 
evidence suggest that HDAC6 also plays a role in the nucleus. It interacts with several 
nuclear proteins, including HDAC11 (Gao et al., 2002), sumoylated p300 (Girdwood et al., 
2003), transcriptional corepressors such as ETO2 and L-CoR, and sequence specific 
transcription factors such as NF-kB and Runx2 (Yang & Gregoire, 2005). HDAC10 is also a 
class IIb histone deacetylase. The N-terminal half of HDAC10 is more similar to the first 
catalytic domain of HDAC6 than to the second (Guardiola & Yao, 2002). The C-terminal half 
of HDAC10 is leucine rich and shows limited sequence similarity to the second deacetylase 
domain of HDAC6 (Guardiola & Yao, 2002,Yang & Seto, 2008), but its function remains 
elusive. 
Class IV deacetylase, HDAC11, is a highly conserved deacetylase. It shows sequence 
similarity to class I and II HDACs. Little is known about its function or regulation (Gao et 
al., 2002). 
Class III deacetylases and function: Mammals have seven Sir2 homologs (sirtuins, SIRT1–7). 
These proteins have a highly conserved NAD-dependent sirtuin core domain, first identified 
in the founding yeast SIR2 protein. Mammalian sirtuins have diverse cellular locations, 
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multiple substrates, and affect a broad range of cellular functions (Haigis & Guarente, 2006). 
Three mammalian sirtuins (SIRT1, SIRT6, and SIRT7) are localized to the nucleus. SIRT1 is 
most extensively studied, has more than a dozen known substrates (Haigis & Guarente, 2006). 
SIRT1 regulates histone acetylation levels (mainly K16-H4 and K9-H3 positions) (Vaquero et 
al., 2004,Pruitt et al., 2006), and the acetylation of transcription factors such as p53 (Vaziri et al., 
2001), p300 histone acethyltransferase (Bouras et al., 2005), E2F1 (Wang et al., 2006), the DNA 
repair ku70 (Cohen et al., 2004), NF-KB (Yeung et al., 2004), and the androgen receptor (Fu et 
al., 2006). It is also responsible for tissue metabolism, cellular oxidative stress and DNA repair 
(Finkel et al., 2009, Uhl et al., 2010). SIRT6 and SIRT7 may also be important regulators of DNA 
damage and metabolism (Finkel et al., 2009). SIRT2 is a predominantly cytoplasmic protein. It 
colocalizes with tubulin, and can deacetylate a number of substrates in vitro, including ǂ 
tubulin and histones (North et al., 2003). SIRT2 may be important in regulating mammalian 
cell cycle (Dryden et al., 2003). SIRT3-5 are localized at the mitochondria and are important for 
micochondria energy usage (Pereira et al., 2011).  
3. Connections between DNA methylation and histone deacetylation for gene 
silencing 
Alteration of DNA methylation affects histone acetylation, or vice versa: Both DNA methylation 
and hypoacetylation of histones H3 and H4 are frequently associated with silent 
genes(Dobosy & Selker, 2001). For example, in DNMT1 knockout cancer cells there is an 
increase in the amount of acetylated forms of histone H3 and a decrease in that of the 
methylated forms of histone H3. These changes are associated with a loss of interaction of 
HDACs and the heterochromatin protein HP1 with histone H3. These data strongly indicate 
that histone hyperacetylation is not always a result of a loss of HDAC activity, but that it 
could be due to a loss of HDACs targeted to specific DNA sequences. One possible 
explanation is that changes in DNA methylation also cause histone modification due to 
direct interactions between the enzymes regulating different epigenetic modifications 
(Espada et al., 2004). The evidence supporting the communication between DNA 
methylation and histone deacetylation has been demonstrated from inhibitor studies. 
HDAC inhibitors do not only change acetylation of histones, but also induce DNA 
demethylation. Using DNA demethylating agents, like 5-aza-2’-deoxycytidine, in 
combination with HDAC inhibitors changes the status of DNA methylation, reactivates 
gene transcription, and inhibits cancer cell growth (reviewed in (Dobosy & Selker, 
2001,Hellebrekers et al., 2007)). Recent studies show that histone deacetylase inhibitor 
Trichostatin A (TSA) treatment reduces global DNA methylation and DNMT1 protein level, 
alters DNMT1 nuclear dynamics and interactions with chromatin. The mechanisms 
underlying these effects are apparently distinct from the mechanisms of action of the DNMT 
inhibitor 5-Azacytidine (Arzenani et al., 2011). Therefore, communication between histone 
deacetylation and DNA methylation is likely to be a dynamic process in the regulation of 
gene silencing.  
Connections through methyl-CpG-binding proteins: Early studies show that DNA methylation 
can lead to transcriptional repression through interaction with methyl-CpG-binding 
proteins (Nan et al., 1997). Methyl-CpG-binding proteins are a group of proteins that bind to 
methylated CpG sites through their mentyl-CpG-binding domain (MBD). The founding 
member of the MBD family was MeCP2 (Lewis et al., 1992). It is a multidomain protein and 
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is associated with and localized to densely methylated chromatin regions. This protein also 
contains a transcriptional repression domain (TRD). Subsequently, MBD1 to MBD4 were all 
discovered as EST clones with sequence similarity to the MBD motif of MeCP2 (Hendrich & 
Bird, 1998). All these proteins, except MBD3, contain both MBD domain and TRD domain, 
and recognize methylated DNA. The identification of methyl-CpG binding proteins (MBDs) 
leads to insights into the communication between DNA methylation and HDACs as all 
MBDs are components of co-repressor complexes that contain histone deacetylases (Fatemi 
& Wade, 2006).  
Transcription repression mediated through MeCP2 requires both MBD and TRD domains. 
It was then demonstrated that MeCP2 can interact with transcription repressor SIN3. 
Furthermore, the region of interaction with Sin3 on MeCP2 significantly overlapped the 
TRD domain and tethering of the TRD resulted in repression that is sensitive to inhibitors 
of histone deacetylase. Thus, recruitment of the Sin3 repressive complex containing 
HDAC1 and HDAC2 to the methylation sites in the gene promoters results in a 
deacetylated repressive chromatin structure (Jones et al., 1998,Nan et al., 1997) . In neural 
progenitor/ES cells, genes are regulated by the REST corepressor complex which contain 
CoREST and histone deacetylases. MeCP2/Sin3 corepressor complexes can interact with 
REST repressor complex in the promoter region, resulting in gene inactivation (Ballas et 
al., 2005). It is noteworthy that MeCP2 can mediate transcriptional repression in both 
HDAC-dependent and –independent manners (Kaludov & Wolffe, 2000). In addition, a 
recent study suggests that MeCP2 can also function as an activator of gene transcription 
by recruiting transcriptional activator CREB1 to an activated gene promoter (Chahrour et 
al., 2008).  
MeCP1 complex was purified using methylated DNA oligoes (Meehan et al., 1989). Later 
studies demonstrated that MeCP1 complex contains MBD2, HDAC1, HDAC2, and RbAp48 
(Ng et al., 1999). Exogenous MBD2 represses transcription and this repression can be 
relieved by the deacetylase inhibitor trichostatin A (Ng et al., 1999). Interestingly, MBD2 is 
also capable of recruiting Mi-2/NuRD complex to methylated DNA through its 
heterodimerization with MBD3 (Feng & Zhang, 2001,Hendrich et al., 2001). This suggests an 
interplay of DNA methylation, nucleosome remodeling and histone deacetylation in gene 
silencing. In addition, activity of MBD2 is modulated through association with cofactors. A 
recent study indicates that methyl-CpG-binding protein 3-like-2 (MBD3L2) may function as 
a transcriptional modulator in MBD2-MeCP1-NuRD-mediated methylation silencing (Jin et 
al., 2005). MBD3L2 can convert inactivated genes to activated genes by displacing MBD2 
present in the NuRD complex, which sequesters the MeCP1-NuRD complex away from 
methylated DNA. In addition, MBDin (Lembo et al., 2003) and transforming-acid-coiled-coil 
3 (TACC3) can interact with MBD2 and reactivate MBD2-repressed genes through different 
regulation mechanisms. The recruitment of MBDin to MBD2 disrupts the association of 
MBD2 to its repressor complex (Lembo et al., 2003). Unlike MBDin, TACC3 can reactivate 
methylated genes by forming a complex with MBD2 and histone acetyltransferase PCAF 
(Angrisano et al., 2006). 
MBD1 represses transcription of methylated reporter constructs. The repression requires 
both the TRD and MBD motifs and is sensitive to HDAC inhibitors (Ng et al., 2000). 
However, it remains undetermined which HDACs associate with the MBD1 complex. 
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Connections through DNMT-HDAC interaction: DNMTs, including DNMT1 and DNMT3s, can 
directly interact with HDAC1 and HDAC2 to repress gene transcription in vitro and in vivo 
(Geiman & Robertson, 2002). A study shows that repression of gene transcription by direct 
interaction between DNMT3A and HDAC1/2 can be abolished by sumoylation of 
DNMT3A, but not the other interaction partner, DNMT3B (Ling et al., 2004), which suggests 
a specific regulation of DNMT3A-mediated gene silencing. Notably, DNMT3L, which lacks 
the catalytic domain, has been shown to bind to HDAC1 and regulate DNA methylation 
independent of methylating activity (Deplus et al., 2002).  
Another connection between DNA methyl transferase and deacetylase is that DNMT1 is 
stabilized by HDAC1 and the deubiquitinase HAUSP (herpes virus-associated ubiquitin-
specific protease). In human colon cancers, the abundance of DNMT1 is correlated with that 
of HAUSP. HAUSP knockdown rendered colon cancer cells more sensitive to killing by 
HDAC inhibitors both in tissue culture and in tumor xenograft models (Du et al., 2010). 
HDACs may also be involved in regulating DNMT1 gene expression as HDAC inhibitor 
TSA decreased DNMT1 mRNA stability and reduced its transcript’s half-life (Januchowski 
et al., 2007). 
DNA methylation and Histone deacetylation, who comes first? Although it is well accepted that 
cross-talk between DNA methylation and histone deacetylation plays a pivotal role in gene 
silencing, it is still unclear which event is the dominant epigenetic determinant in this 
communication process. Some evidence suggests that DNA methylation may be the primary 
event to trigger histone deacetylation and lead to gene silencing (Irvine et al., 2002,Jones et 
al., 1998,Kaludov & Wolffe, 2000,Kudo, 1998,Nan et al., 1998,Rountree et al., 2000). 
Controversially, loss of histone acetylation may guide the local DNA hypermetylation and 
initiate transcriptional repression. Felsenfeld’s group has shown that chicken ǃ-globin 
insulator recruits HAT to establish a high level of histone acetylation which prevents 
promoter CpG methylation by blocking binding of the transcriptional repressor complex to 
the promoters (Mutskov et al., 2002). A global methylation study shows that histone 
hypoacetylation caused by TSA induces a significant decrease in global methylation (Ou et 
al., 2007). In addition, inhibition of HDAC1 by sodium butyrate induces promoter 
demethylation and reactivation of RARbeta2 in colon cancer cells (Spurling et al., 2008). A 
recent study in Neurospora crassa found that specific deacetylation of histone H2B and H3 is 
required for DNA methylation and heterochromatin formation (Smith et al., 2010). These 
results indicate that histone deacetylation status is crucial to sustaining DNA methylation of 
the promoters and gene silencing.  
4. Aberrant DNA methylation and histone deacetylation in cancer  
4.1 Aberrant DNA methylation and DNMTs recruitment in cancer 
Altered methylation patterns are found in the majority of tumor types. Methylation changes 
generally occur early in cancer development, which supports the hypothesis that epigenetic 
changes precede cancer development (Linhart et al., 2007,Belinsky et al., 1998,Derks et al., 
2006,Palmisano et al., 2000). A hallmark of many cancers is global hypomethylation and 
regional hypermethylation of CpG islands. This local hypermethylation in cancer is usually 
found on CpG islands associated with promoters of tumor suppressors or other genes 
involved in cell cycle regulation, leading to inactivation of these genes. Promoter 
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hypermethylation also facilitates mutations in these regions as methylated cytosine residues 
are spontaneously deaminated to thymine residues, causing mutational silencing of the genes 
(Sulewska et al., 2007,Fryxell & Zuckerkandl, 2000,Rideout et al., 1990). This hypothesis 
explains the high incidence of CpG to TpG transition mutations observed in the promoters of 
tumor suppressors, for example, the p53 tumor suppressor gene (Rideout et al., 1990).  
The effects of global hypomethylation are more varied and not well understood. In mouse 
models, hypomethylation has been shown to induce genomic instability and tumorigenesis 
(Gaudet et al., 2003,Eden et al., 2003). It has been suggested that global hypomethylation can 
induce reexpression of normally silenced genes, some of which may be oncogenic. Genes 
reactivated by global hypomethylation can include silenced oncogenes, imprinted genes, 
genes on the inactivated X-chromosome (Sharp et al., 2011), endogenous retroviruses and 
transposons (Yoder et al., 1997), as well as silenced drug resistance genes (Chekhun et al., 
2007). For example, a cell-cell adhesion glycoprotein P-cadherin is often overexpressed in 
breast cancer, but not in normal breast tissue. The aberrant expression of P-cadherin in 
breast cancer is regulated by gene promoter hypomethylation. (Paredes et al., 2005). A 
similar mechanism regulates overexpression of cyclin D2 in gastric and ovarian cancer 
(Sakuma et al., 2007,Oshimo et al., 2003), and MAGE in melanomas (De Smet et al., 2004). 
Global hypomethylation also induces chromosomal instability by a mechanism that is not 
well understood; one possible cause is a large number of derepressed transposons and 
retroviruses created by this hypomethylated state (Florl et al., 1999,Howard et al., 2008).  
Tumor heterogeneity is a major barrier to effective cancer diagnosis and treatment. Recent 
studies suggest that methylation patterns can be different in different cancer types and 
tumor stages (Wermann et al., 2010). Epigenetic analysis of large gene panels and genome-
wide screening of DNA methylation levels discovered that overall methylation patterns can 
be used as biomarkers for cancer risk and/or tumor type (Kondo & Issa, 2010,Figueroa et al., 
2010,Hawes et al., 2010,Worthley et al., 2010). Cancer-specific differentially methylated 
regions (cDMRs) were identified; methylation variation within these cDMRs distinguishes 
various cancers from normal tissue, with intermediate variation in adenomas (Hansen et al., 
2011). Whole-genome bisulfite sequencing shows these variable cDMRs are related to loss of 
sharply delimited methylation boundaries at CpG islands. It suggests that the loss of 
epigenetic stability of well-defined genomic domains underlies increased methylation 
variability in cancer and may contribute to tumor heterogeneity. The distinct methylation 
patterns can be used not only to differentiate carcinoma from other tumor types, but also to 
predict tumor progression stage, with potential clinical applications in diagnosis and 
prognosis (Hernandez-Vargas et al., 2010).  
Exact nature of the defect in the cellular methylation machinery in tumor cells remains 
unknown. It is proposed that inappropriate DNMT expression pattern or timing during the 
cell cycle could disrupt the regulation of DNA methylation patterns as DNMT1, 3A, and 3B 
are expressed differentially during the cell cycle (Robertson, 2001). Global hypomethylation 
in cancer cells may also be due to upregulation of DNA demethylase system (Rai et al., 
2010). Increased expression of DNMTs can result in hypermethylation of CG islands in 
cancer cells and may play important roles in malignant progression of cancer, leading to 
aberrant methylation in many important tumor suppressor genes. In fact, it had been shown 
that DNMT overexpression is an early and significant event in urothelial, hepatic, gastric, 
pancreatic, lung, breast, and uterine cervix carcinogenesis (Daniel et al., 2011). 
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Although the DNMT1 and DNMT3 family of proteins have been considered either 
maintenance or de novo methyltransferases, respectively, it is likely that all three DNMTs 
possess both functions in vivo, particularly during carcinogenesis (Robertson, 2001). DNMT1 
has been shown to be essential for the survival and proliferation of human cancer cells 
(Chen et al., 2007). Increased DNMT1 protein expression correlates significantly with 
frequent DNA hypermethylation of multiple CpG islands, poorer tumor differentiation and 
malignant progression (Etoh et al., 2004,Nakagawa et al., 2005,Saito et al., 2003). In bladder 
cancer, progressive increase of expression of DNMT1 protein occurs during the 
precancerous stages (Nakagawa et al., 2003). Depletion of DNMT1 resulted in lower cellular 
maintenance methyltransferase activity, global and gene-specific demethylation and re-
expression of tumor-suppressor genes in human cancer cells. Specific depletion of DNMT1 
but not DNMT3A or DNMT3B markedly potentiated the ability of 5-aza-2'-deoxycytidine to 
reactivate silenced tumor-suppressor genes, indicating that inhibition of DNMT1 function is 
the principal means by which 5-aza-2'-deoxycytidine reactivates genes. These results 
indicate that DNMT1 is necessary and sufficient to maintain global methylation and 
aberrant CpG island methylation in human cancer cells (Robert et al., 2003).  
DNMT3B depletion reactivated methylation-silenced gene expression but did not induce 
global or juxtacentromeric satellite demethylation as did specific depletion of DNMT1, 
indicating that DNMT3B has significant site selectivity that is distinct from DNMT1 
(Beaulieu et al., 2002). It is shown that DNMT3B1 but not DNMT3A1 efficiently methylates 
the same set of genes in tumors and in nontumor tissues, demonstrating that de novo 
methyltransferases can initiate methylation and silencing of specific genes in phenotypically 
normal cells. This suggests that DNA methylation patterns in cancer are the result of specific 
targeting of at least some tumor suppressor genes, such as  Sfrp2, Sfrp4, and Sfrp5, rather 
than of random, stochastic methylation followed by clonal selection due to a proliferative 
advantage caused by tumor suppressor gene silencing (Linhart et al., 2007).  
4.2 HDACs and cancer 
One common theme in cancer cells is elevated HDAC expression and global 
hypoacetylation. Loss of acetylated Lys16 (K16-H4) and trimethylated Lys20 (K20-H4) of 
histone H4 may be a common event in human cancer (Fraga et al., 2005), while other studies 
also show that the decrease in histone acetylation is not only involved in tumorogenesis, but 
also in tumor invasion and metastasis (Yasui et al., 2003). 
It has become increasingly clear that class I HDAC enzymes are clinically relevant to cancer 
therapy (Haberland et al., 2009,Ropero & Esteller, 2007). Increased HDAC1 expression levels 
have been reported to in a variety of cancers, such as gastric (Choi et al., 2001), prostate 
(Halkidou et al., 2004), colon (Wilson et al., 2006) and breast (Zhang et al., 2005) carcinomas. 
Overexpression of HDAC2 has been found in cervical (Huang et al., 2005), gastric (Song et 
al., 2005), and colorectal carcinoma (Ashktorab et al., 2009). Other studies have reported 
high levels of HDAC3 (Wilson et al., 2006) expression in colon cancer specimens. HDAC8 
has been found to be associated with various types of leukemia (Balasubramanian et al., 
2008). HDAC1, 6 and 8 could also be important for breast cancer invasion (Park et al., 2011). 
These observations suggest that transcriptional repression of tumor-suppressor genes by 
overexpression or aberrant recruitment of HDACs to their promoter regions could be a 
common phenomenon in tumor onset and progression. It is now known that HDACs have 
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been associated with the deregulation of a number of well-characterized cellular oncogenes 
and tumor-suppressor genes. For example, Class I HDACs promote cell proliferation by 
inhibiting p21 and p27 promoter activity (Lagger et al., 2002,Wilson et al., 2006). In some 
tumors, p21(WAF1/cip1) is epigenetically inactivated by hypoacetylation of the promoter, 
and treatment with HDAC inhibitors leads to inhibition of tumor cell growth and an 
increase in both acetylation of the promoter and gene expression (Gui et al., 2004). The 
transcription factor Snail recruits HDAC1, HDAC2, and the corepressor complex mSin3A to 
the E-cadherin promoter to repress its expression (Peinado et al., 2004). Downregulation or 
loss of function of E-cadherin has been implicated in the acquisition of invasive potential by 
carcinomas (Hajra & Fearon, 2002), and so aberrant recruitment of HDACs to this promoter 
may have a crucial role in tumor invasion and metastasis. The role of HDACs in cancer is 
not restricted to their contribution to histone deacetylation, but also includes their role in 
deacetylation of non-histone proteins. For example, HDAC1 interacts with the tumor 
suppressor p53 and deacetylates it in vivo and in vitro (Juan et al., 2000,Luo et al., 2000). p53 
is phosphorylated and acetylated under stress conditions. Since lysine residues acetylated in 
p53 overlap with those that are ubiquitinated, p53 acetylation serves to promote protein 
stability and activation, inducing checkpoints in the cell-division cycle, permanent cell-
division arrest, and cell death. Aberrant recruitment of HDACs to specific promoters 
through the interaction with fusion proteins that result from chromosomal translocations in 
hematological malignancies has also been intensively studied. In acute promyelocytic 
leukemia, leukemic fusion between the PML (promyelocytic leukemia) gene and the retinoic 
acid receptor (RAR) gene suppresses transcription through recruitment of HDACs. Thus, 
cancer cells are unable to undergo differentiation, leading to excessive proliferation (Lin et 
al., 2001,He et al., 2001). Similar phenomena have been described for the RARǂ-PLZF 
(promyelocytic leukemia zinc finger protein) fusion, the AML1 (acute myelocytic leukemia 
protein1)-ETO fusion, and for the myc/Mad/Max signaling pathway involved in solid 
malignancies (Minucci et al., 2001,Ferrara et al., 2001,Kitamura et al., 2000,David et al., 1998). 
Class II HDACs have also been shown to associate with various cancer types. Inhibition of 
class II HDACs induces p21 expression in breast cancer cell lines, suggesting that class II 
HDAC subfamily may exert specific roles in breast cancer progression (Duong et al., 2008). 
HDAC4 inhibits p21 gene expression through interaction with Sp1 at p21 proximal 
promoter. Induction of p21 mediated by silencing of HDAC4 arrested cancer cell growth in 
vitro and inhibited tumor growth in an in vivo human glioblastoma model (Mottet et al., 
2009). HDAC4 also interacts with PLZF and represses PLZF-RARǂ fusion protein activity 
(Chauchereau et al., 2004,Yuki et al., 2004). In the prostate cancer model, HDAC4 is 
recruited to the nuclei of cancer cells, where it may exert an inhibitory effect on 
differentiation and contribute to the development of the aggressive phenotype during late 
stage of prostate cancer (Halkidou et al., 2004). HDAC5 and HDAC9 are significantly 
upregulated in high-risk medulloblastoma in comparison with low-risk medulloblastoma, 
and their expression is associated with poor survival (Milde et al., 2010). Higher expression 
of HDAC7 and HDAC9 is associated with pancreatic adenocarcinomas and poor prognosis 
in childhood ALL (Ouaissi et al., 2008, Moreno et al., 2010).  
Class IIb deacetylase HDAC6 is linked to breast cancer. HDAC6 is expressed at significantly 
higher levels in breast cancer patients with small tumors and low histologic grade, and in 
estrogen receptor ǂ- and progesterone receptor-positive tumors. Furthermore, patients with 
high levels of HDAC6 mRNA tended to be more responsive to endocrine treatment than 
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those with low levels, indicating that HDAC6 may be an early prognosis marker (Zhang et 
al., 2004,Saji et al., 2005). Overexpression of HDAC6 in MCF-7 breast cancer cells increased 
cell motility, suggesting a role for HDAC6 in metastases (Saji et al., 2005). HDAC6 has 
additional functions in integrating signaling and cytoskeleton remodeling. It is shown that 
cortactin, a genuine substrate of HDAC6, is overexpressed in several carcinomas (Zhang et 
al., 2007,Luxton & Gundersen, 2007). Therefore, HDAC6 could be a viable target for cancer 
therapy. There is emerging evidence that inhibiting HDAC6 mediated aggresome pathway 
leads to the accumulation of misfolded proteins and apoptosis in tumor cells through 
autophagy (Rodriguez-Gonzalez et al., 2008). 
Class III deacetylases, the NAD+ dependent SIRT proteins, are also connected to cancer. For 
instance, SIRT1 is upregulated in human lung cancer, prostate cancer and leukemia and has 
been found to be downregulated in colon tumors (Reviewed in (Ropero & Esteller, 2007)). 
SIRT1 is also responsible for the loss of the acetylation levels of K16-H4 and K9-H3, which is 
common in human cancer at early cancer development (Fraga et al., 2005). Upregulation of 
SIRT1 expression in human cancer can also induce deregulation of key proteins, such as p53 
and E2F (Chen et al., 2005,Wang et al., 2006).  
5. Epigenetic agents and combinatorial therapies in cancer treatment 
5.1 DNA methylation inhibitors 
The most common DNMT inhibitors in clinical use, 5-azacytidine (5-aza) and 5-aza-2'-
deoxycytidine (decitabine), were synthesized almost 50 years ago (Sorm et al., 1964). 5-aza is 
a cytidine analog. It was originally developed as a nucleoside antimetabolite that could be 
incorporated into nucleic acids to induce chromosome breakage and mutations, and inhibit 
protein synthesis by interfering with tRNA and rRNA function (Viegas-Pequignot & 
Dutrillaux, 1976,Cihak, 1974,Karon & Benedict, 1972). Subsequently it was shown that 5-aza 
incorporates into nucleic acids and covalently binds to DNMTs, leading to a rapid loss of 
methylation as a result of DNMT depletion (reviewed in (Christman, 2002)). Decitabine is a 
very structurally similar compound that was suggested as a less toxic and more specific 
alternative to 5-aza, as it is not integrated into RNA (Vesely & Cihak, 1977,Bouchard & 
Momparler, 1983)(reviewed in (Christman, 2002). In the last twenty years, 5-aza and 
decitabine have been extensively tested in the clinic and approved by the FDA for treatment 
of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML), respectively 
(section 5.3). However, both 5-aza and decitabine are toxic and highly unstable in aqueous 
solutions (reviewed in (Stresemann & Lyko, 2008). This makes them difficult to use in 
clinical settings, especially in solid tumors, so there is a need for other DNMT inhibitors 
with more favorable properties. Several new DNMT inhibitors have been designed in the 
last two decades, but most have minimal efficacy in vivo, with the exception of zebularine 
(reviewed in (Brueckner et al., 2007)). Zebularine is also a cytidine analog, but it is more 
stable and less toxic than 5-aza and decitabine. Zebularine was originally developed as a 
cytidine deaminase inhibitor, but was later shown to potently inhibit DNMT activity (Zhou 
et al., 2002) and cancer cell growth (Cheng et al., 2004,Balch et al., 2005) (reviewed in (Yoo et 
al., 2004). The mechanism of action is largely the same as 5-aza and decitabine, and although 
its IC50 is higher, lower toxicity and longer biological half-life makes it an attractive 
candidate for pre-clinical testing and future clinical trials. 
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5.2 Histone deacetylase inhibitors 
HDAC inhibitors were discovered in the 1970s, when it was shown that treatment of cells 
with sodium butyrate led to hyperacetylation of histones (Candido et al., 1978). Sodium 
butyrate was found to be difficult to use clinically due to its poor pharmacological 
properties (Miller et al., 1987). In the following two decades, several more promising 
antitumor agents that inhibit HDACs were discovered. These include valproic acid (VPA), 
suberoylanilide hydroxamic acid (SAHA, trade name Vorinostat), Trichostatin A (TSA), and 
depsipeptide or FK228 (FR901228, trade name Romidepsin). All of them inhibit HDACs by 
binding to the active site (reviewed in (Marks & Dokmanovic, 2005), (Martinet & Bertrand, 
2011)), resulting in release of epigenetic repression. HDAC inhibitors also synergize with 
DNA damaging treatments such as radiotherapy or chemotherapy with nucleoside analogs 
(Munshi et al., 2005,Chinnaiyan et al., 2005), probably because HDACs are also involved in 
DNA replication and DNA repair (section 2.2) (Spange et al., 2009). The three most popular 
HDAC inhibitors in widespread clinical use today are VPA, SAHA, and depsipeptide, while 
Trichostatin A is not used clinically due to toxic side effects. VPA has the longest clinical 
history as it has been used for treatment of epilepsy since the 1960s. It inhibits proliferation 
of cultured cancer cells at millimolar concentrations and shows synergistic effects in 
combination with decitabine or hydralazine (Table 1), and it is currently in clinical trials for 
multiple kinds of cancer (section 5.4). SAHA is more potent, as it was shown to induce 
growth inhibition, differentiation or apoptosis in cultured cancer cells (Richon et al., 
1996,Butler et al., 2000) and inhibit cancer cell growth synergistically with decitabine or 
zebularine at micromolar concentrations (Table 1); however, it has a short biological half-life 
of about 2 hours (Kelly et al., 2005). Depsipeptide, discovered in 1994 (Ueda et al., 1994), is a 
cyclic tetrapeptide that preferentially targets class I HDACs (Furumai et al., 2002). It shows 
synergistic effects in combination with decitabine, zebularine, Trichostatin A, and 5-aza, and 
inhibits cancer cell proliferation at sub-micromolar concentrations (Table 1). Currently, 
SAHA and depsipeptide have been approved by FDA for treatment of cancer, while VPA is 
still in clinical trials (reviewed in section 5.4). 
5.3 DNA methylation and HDAC inhibitors in combination in cancer cells and mouse 
models 
DNMT inhibitors and HDAC inhibitors in combination show synergistic growth inhibition 
in cancer cell lines and in animal models of cancer. Table 1 summarizes combined 
treatments with DNMT and HDAC inhibitors in cancer cell lines, organized by cancer type, 
in alphabetical order. Combination treatments caused synergistic growth inhibition and/or 
differentiation in the majority of cancer cell lineages tested, including leukemia and 
lymphoma, small-cell and non-small cell lung cancer, esophageal, liver, breast, and 
pancreatic cancers (Table 1 for references). This growth inhibition is generally followed by 
apoptosis as drug dose is increased. 
DNMT inhibitors and HDAC inhibitors synergistically affect chromatin state and lead to a 
more pronounced re-expression of epigenetically silenced tumor suppressor genes and cell 
cycle regulators (Cameron et al., 1999) (see Figure 1). For example, decitabine plus VPA 
synergistically induce NY-ESO-1 antigen in glioma cells (Oi et al., 2009), making them a 
target for immunotherapy. Epigenetic agents are more effective when key tumor suppressor  
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Fig. 1. HDAC and DNMT inhibitors synergistically affect chromatin state, leading to an 
open chromatin structure and derepression of tumor suppressors, resulting in growth 
inhibition and apoptosis. Open chromatin structure, as well as DNA repair inhibition 
induced by HDAC inhibitors, makes cells more susceptible to DNA damage induced by 
DNMT inhibitors, DNA damaging treatments such as radiotherapy, and epigenetic 
derepression of mobile DNA elements. DNA damage also leads to cell death. 
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genes, such as CDKN2A (p16) and p18, are epigenetically silenced (Table 1) (Gore et al., 
2006), suggesting that the induction of silenced tumor suppressor genes may be critical for 
therapeutic effect. For example, the efficacy of DNMT inhibitors decitabine or zebularine 
combined with the HDAC inhibitor depsipeptide in lung and breast tumor cells with 
defined CDKN2A status was described recently (Chen et al., 2010). It was shown that non-
small cell lung cancer cells with methylated CDKN2A are significantly more sensitive to 
methylation inhibitors than cell lines with deleted CDKN2A, and the combination of 
zebularine/depsipeptide results in a synergistic effect on cell growth inhibition that is also 
linked with the presence of epigenetically silenced CDKN2A (Chen et al., 2010). These data 
strongly support the importance of prospective pre-selection of patients in future clinical 
trials and suggest CDKN2A status as a key biomarker for DNMT/HDAC inhibition studies. 
DNMT inhibitors and HDAC inhibitors do not necessarily act only on DNA methylation 
and histone acetylation, respectively, but have other functions as well (also see section 2). It 
was shown that HDAC inhibitors can affect DNA methylation (Sarkar et al., 2011), and 
DNMT inhibitors can affect histone methylation (Kondo et al., 2003). When these agents are 
used in combination, one inhibitor can affect epigenetic changes brought about by the other 
(Dobosy & Selker, 2001,Oi et al., 2009). DNMT inhibitors can also inhibit proliferation of 
cancer cells by causing DNA damage and chromosomal instability. Most DNMT inhibitors 
in widespread use are cytidine analogs (decitabine, 5-aza, zebularine, etc.) that can integrate 
into DNA and introduce perturbations in its normal structure leading to strand breaks 
(Karon & Benedict, 1972), or derepress endogenous transposons and retroviral sequences 
silenced by methylation (Groudine et al., 1981), which can lead to DNA damage and 
chromosomal instability as well (see Figure 1). These effects are likely augmented by HDAC 
inhibitors, which can introduce further changes into DNA structure, contribute to the 
activation of silenced transposons and retroviral sequences, or inhibit DNA damage repair 
(see Figure 1). For example, it was shown that depsipeptide can slow down removal of 
decitabine from the DNA (Chai et al., 2008) (possibly by inhibiting DNA repair 
mechanisms), suggesting an explanation for synergy between these compounds as 
decitabine staying on the DNA longer would lead to greater DNA demethylation and DNA 
damage. Also, DNA repair inhibition or chromatin structure changes may account for the 
fact that the interactions between DNMT inhibitors and HDAC inhibitors can depend on the 
order in which they are used. For example, depsipeptide treatment for 24 hours followed by 
5-aza for 24 hours caused a synergistic induction of Gadd45, but this effect was not present 
when the compounds were used simultaneously or in the reverse order (Jiang et al., 2007).  
HDAC inhibitors and DNMT inhibitors can also synergize with radiotherapy(Munshi et al., 
2005,Chinnaiyan et al., 2005), CDK inhibitors (Almenara et al., 2002), TRAIL cytokine 
(Kaminskyy et al., 2011), and conventional chemotherapy agents such as cisplatin (Shang et 
al., 2008), paclitaxel, doxorubicin , and 5-fluorouracil (Mirza et al., 2010). Furthermore, they 
can induce a response in tumors which are resistant to chemotherapeutic agents (Plumb et 
al., 2000). In addition to the observation that HDAC and DNMT inhibitors can reactivate 
epigenetically silenced tumor suppressor genes and/or inhibit DNA repair, making 
conventional treatment regimens more effective, another possible mechanism behind this 
synergy is that the open chromatin structure induced by epigenetic agents makes DNA 
more accessible for chemotherapy drugs and radiation (Falk et al., 2008)(see Figure 1). These 
results show clinical potential for using combinations of epigenetic drugs and conventional 
agents, especially to overcome or prevent chemotherapy resistance (reviewed by (Gravina et 
al., 2010) and (Thurn et al., 2011)).  
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Several other conclusions can be drawn from the work summarized in Table 1. Cytidine 
analogs (decitabine, 5-aza, and zebularine) synergize well with HDAC inhibitors when 
acting on cultured cancer cells, making these combinations good candidates for future 
clinical trials. However, there are long-term cancer risks associated with using nucleoside 
analogs, as they induce DNA damage, increasing the probability of mutations. Among the 
HDAC inhibitors, depsipeptide is the most tested in culture over the recent years, because it 
preferentially inhibits class I HDACs (Furumai et al., 2002) that have been shown to be 
overexpressed and associated with poor prognosis in multiple kinds of cancer(Nakagawa et 
al., 2007,Weichert et al., 2008,Weichert et al., 2008). 
The effects of epigenetic drugs on tumor growth in xenograft and in genetically engineered 
mouse models (GEMM) (Tables 2 and 3) are similar to the effects observed in cancer cell 
lines (Table 1).  
Treatment of mice with DNMT1 and HDAC inhibitors causes induction of tumor suppressor 
genes and pro-apoptotic proteins leading to inhibition of tumor growth and apoptosis. 
Epigenetic agents were tested in xenografts (Table 2), and GEMMs, which more closely 
resemble human cancers (Becher & Holland, 2006)(Table 3). Consistent growth inhibition by 
epigenetic agents (Tables 2 and 3) further indicated that DMNTs and HDACs were potential 
targets for future clinical trials. The effects of epigenetic agents were similar using several 
distinct drugs and tumor models – e.g. p21 protein expression was induced with five different 
drugs (SAHA, MS-275, PXD101, LBH-589, decitabine) in xenograft models of breast, lung, and 
ovarian cancer (Table 2). CDKN1A/p21 was also induced by zebularine in a transgenic mouse 
model of breast cancer (Table 3). Other genes induced by epigenetic agents in mouse models 
included tumor suppressors such as p16 and MLH-1 and pro-apoptotic proteins Bax, caspase 
3/7, and death receptor proteins 4 and 5 (Table 2). In contrast, expression of proto-oncogenes 
such as cyclin D1 and VEGF and anti-apoptotic proteins Bcl-2 and Bcl-XL was suppressed 
(Tables 2). These results are similar to what was observed in cancer cell lines, where epigenetic 
agents induced the expression of p16, p21, caspase 3 and MLH1, while downregulating Bcl-2 
and other anti-apoptotic proteins (Table 1).  
Most epigenetic agents that were tested in mouse models, e.g. decitabine, SAHA, and MS-
275, are currently in clinical trials (see section 5.4). Several xenograft and GEMM studies 
focused on a novel DNMT inhibitor, zebularine, that is not yet approved for human use 
(Table 2 and 3). It has been shown that zebularine can be administered orally due to its 
longer half-life than other DNMT inhibitors and can inhibit tumor growth and induce 
expression of tumor suppressor genes (Cheng et al., 2003) and our unpublished observations 
(Chen et al, unpublished data). Subsequent xenograft studies showed that short-term 
treatment with zebularine (Dote et al., 2005) or even a single injection (Neureiter et al., 2007) 
can inhibit tumor growth. The GEMM studies focused on long-term therapy with an oral 
formulation of zebularine for intestinal adenomas (Yoo et al., 2008) and mammary tumors 
(Chen et al, unpublished data). In our unpublished study, high-dose zebularine treatment 
delayed tumor growth and reduced tumor burden in MMTV-PyMT mouse model. In the 
Yoo et al. study, continuous treatment of Min transgenic mice with low-dose zebularine 
prevented polyp formation in the majority of treated animals (while controls all developed 
intestinal polyps). This study makes low-dose oral zebularine an attractive target for future 
clinical trials. 
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Abbreviations: 5-FU – 5-fluorouracil, AML - acute myeloid leukemia, CTA – cancer testis antigen, DLBCL diffuse larg
LBH589 – trade name Panobinostat,  PXD101 – trade name Belinostat 
Table 1. Effects of HDAC and DNMT inhibitors on proliferation and gene expression in cancer cell lines
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Combinations of DNMT and HDAC inhibitors were tested in three xenograft models and 
two GEMM’s. Four models showed synergy between DMNT and HDAC inhibitors in the 
delay or reduction of tumor growth (Tables 2, 3). In addition, epigenetic agents in 
combination with chemotherapy drugs such as cisplatin, etoposide, daclizumab or 
bortezomib, enhanced the antitumor effect (Table 2). Animal studies paved the way for 
clinical trials using DNA methylation and HDAC inhibitors alone or in combination with 
chemotherapy (Section 5.4. and Tables 4, 5, 6, 7). 
5.4 DNA methylation and HDAC inhibitors in clinical trials 
The first epigenetic modulator in clinical use was a demethylating agent, 5-azacytidine. A 
phase I clinical trial was first reported in 1972, in which 30 patients with advanced solid 
tumors were treated with 5-azacytidine (Weiss 1972). Responses were seen in 7 of 11 
patients with breast cancer, 2 of 5 patients with melanoma, and 2 of 6 patients with colon 
cancer. However, significant myelosuppression, nausea and diarrhea were observed. In a 
second study conducted in 1973, 37 children with acute leukemia were treated with 5-
azacytidine (Karon 1973). Of the 14 patients with acute myelogenous leukemia (AML) 
enrolled in the trial, 5 achieved a complete remission (CR) lasting at least 2 months. 
Toxicities included myelosuppression, nausea, vomiting, diarrhea, and a transient, pruritic 
rash. Interest in the drug waned in the 1970s and 1980s. However, in 1993, the promising 
results of a single-arm phase I/II trial in patients with myelodysplastic syndrome (MDS, 
types refractory anemia with excess blasts (RAEB-t) and RAEB in transformation (RAEB) 
with 5-azacytidine were published (Silverman 1993). Out of 43 evaluable patients, the 
response rate was 32%, with 5 CRs (10%) and 11 partial remissions (PRs) (22%). An 
interesting finding was that the median time to initial response for several of these trials was 
90 or more days, suggesting that longer assessments were necessary to see a significant 
effect on outcome. Eventually, a phase III trial was conducted, which led to its approval by 
the FDA for use in patients with MDS in 2004 (Table 3) (Silverman 2002). In this study, 191 
patients with all French-American-British (FAB) subtypes of MDS were randomized to 
either best supportive care (BSC), or 5-azacytidine with BSC. The BSC-only patients could 
crossover to the 5-azacytidine arm if they had worsening disease after 4 months on the 
study. The response rate was 23% (7% CR, 16% PR), and median time to leukemic 
transformation or death was 21 months with 5-azacytidine, compared to 13 months for BSC 
(p=0.007). A landmark analysis to eliminate the confounding effect of early crossover to the 
5-azacytidine arm showed a median survival of an additional 18 months for 5-azacytidine 
and 11 months for BSC (p=0.03). The most common adverse events were myelosuppression 
and infection. In a Quality of Life analysis, patients on the treatment arm, and those who 
crossed over, experienced a significant improvement in fatigue, dyspnea and physical 
functioning. 
5-aza-2’-deoxycytidine (decitabine), another demethylating agent that has been extensively 
studied, was first used in clinical trials in patients with acute leukemia, in which 21 children 
and adults with acute lymphocytic leukemia (ALL) and AML were treated (Marmparler 
1985). The response rate was 37%, with 6 CRs (22%) and 4 PRs (15%). There was a 
suggestion that the drug was more effective in AML than ALL, although the sample sizes in 
each group were too small. An analysis of DNA methylation by high-performance liquid  
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chromatography (HPLC) on 2 patient samples showed that decitabine therapy produced > 
70% inhibition in DNA methylation. Decitabine was subsequently studied in patients with 
solid tumors (Abele 1987), where only 1 response in 82 evaluable patients was observed 
(1%), but significant myelosuppression was seen in many patients. A phase III trial 
demonstrated its efficacy compared to BSC in patients with intermediate- (INT-1 and INT-2) 
and high-risk MDS (Table 3), which led to its approval by the FDA in 2006. The response 
rate was significantly better than BSC (30% versus 7%), but there was no significant 
difference in median time to leukemic transformation or death (12.1 versus 7.8 months, p = 
0.16). Cytopenias were again the dominant adverse effect. 
In 2010, Gurion et al. performed a meta-analysis of demethylating agents for the treatment 
of MDS (Gurion 2010). 952 patients with MDS enrolled in 4 randomized controlled clinical 
trials comparing demethylating agents with either BSC or chemotherapy. Treatment with a 
demethylating agent significantly improved overall survival (Hazard Ratio [HR] 0.72, 95% 
CI 0.60-0.85) and the median time to leukemic transformation or death (HR 0.69, 95% CI 
0.58-0.82). In a subgroup analysis of the type of drug, these benefits were seen for 5-
azacytidine but not for decitabine. Both agents improved response rates. However, a higher 
rate of grade 3/4 toxicities was also noted (RR 1.21, 95% CI 1.10 to 1.33). The data, however, 
were not all obtained in randomized trials, and it is possible that the patients who received 
5-azacytidine or decitabine had a better prognosis despite a similar International Prognostic 
Scoring System (IPSS) score. 
Valproic acid was one of the first HDAC inhibitors investigated in clinical trials in cancer 
patients. However, as an anticonvulsant, it was initially explored for seizure prophylaxis 
(Glantz 1996) and for neuropathic pain (Hardy 2001) in cancer patients. In 2005, three 
articles were published, detailing the results of phase II clinical trials of VPA in combination 
with all-trans retinoic acid (ATRA). The three trials included one in older (age ≥ 65) poor-
risk patients with AML or MDS (RAEB) (6 of 11 had hematological improvements, with 
platelet and erythroid response) (Pailatrino 2005), one in poor-risk patients with AML (1 of 
19 evaluable patients had a minor response and 2 patients had a PR and clearance of 
peripheral blasts (Bug 2005)) and one in elderly patients (age ≥ 70) with AML (1 of 11 
patients had CR, 2 patients had CRi (morphological CR with incomplete blood count 
recovery and 2 patients had hematological improvement) (Raffoux  2005). The first clinical 
trial in solid tumors was conducted in 12 patients with cervical cancer (Chavez-Blanco 2005). 
No outcomes were reported, but hyperacetylation of both H3 and H4 in 7 of 12 patients 
were confirmed. The main adverse effects were sedation and fatigue. While valproic acid is 
FDA approved for seizure control, treatment of manic episodes and migraine prophylaxis, it 
is not yet approved for cancer. 
Vorinostat (SAHA) is one of best-studied HDAC inhibitors in clinical trials. The first clinical 
trial was a phase I, dose-finding trial with an intravenous formulation, administered in 2 
different schedules, in a total of 37 patients with advanced cancer (hematologic and solid 
tumors) (Kelly 2003). The maximum tolerated dose was determined (300 mg/m2/day and 
900 mg/m2/day for 5 days for 3 weeks for hematologic and solid malignancies, 
respectively). Grade 3/4 toxicities in patients with hematologic malignancies included 
neutropenia (grade 4), anemia, thrombocytopenia, dyspnea (grade 4), thrombosis, diarrhea, 
constipation and fatigue. Grade 3/4 toxicities in patients with solid tumors included cardiac 
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ischemia (grade 4), acute respiratory distress syndrome, thrombosis, constipation and 
abdominal pain. Four patients with solid tumors had an objective response. Post-therapy 
tumor biopsies confirmed the presence of acetylated histones. FDA approval for vorinostat 
was given in 2006. It was based on the results of two phase II trials (Duvic 2007, Olsen 2007) 
(Table 3). The pivotal trial was a phase IIB single-arm trial with 74 patients with persistent, 
progressive or recurrent cutaneous T-cell lymphoma (CTCL; mycosis fungoides or Sezary 
syndrome subtypes) who were treated with oral vorinostat (Olsen 2007). The response rate 
was approximately 30%. The most common adverse effects were diarrhea, fatigue, nausea 
and anorexia. Grade 3/4 toxicities included fatigue, pulmonary embolism, 
thrombocytopenia and nausea. A second trial in support of vorinostat was a three-arm, non-
randomized, single-center trial in patients with refractory CTCL (Duvic 2007). Thirty-three 
patients were enrolled, and 8 achieved a PR. Again, the most common adverse effects were 
fatigue, thrombocytopenia, diarrhea and nausea, with grade 3/4 thrombocytopenia and 
dehydration. 
Depsipeptide is another HDAC inhibitor that was recently approved by the FDA. The first 
clinical trial reported with this agent was a phase I trial in refractory or advanced solid 
tumors, in which 37 patients received escalating doses of depsipeptide intravenously on 
days 1 and 5 every 21 days (Sandor 2002). The dose-limiting toxicities included fatigue, 
nausea/vomiting, thrombocytopenia (grade 4) and cardiac arrhythmia (grade 4, atrial 
fibrillation). Based on preclinical data, there was a concern for cardiac toxicity, but no 
myocardial damage was evident, with only frequent, reversible ECG ST/T-wave changes 
noted. The maximum tolerated dose was determined to be 17.8 mg/m2. One PR was 
observed in a patient with renal cell carcinoma, and 8 patients had stable disease. Two phase 
II trials led to FDA approval of depsipeptide in 2009, in patients with cutaneous T-cell 
lymphoma who had received at least one prior systemic therapy (Table 3). In the first trial, a 
multi-institutional, international, single-arm study, 96 patients were enrolled (Whittaker 
2010). The response rate was 34%, and 6 patients (6%) achieved a CR. The median duration 
of response was 15 months. The most common adverse events were nausea, vomiting, 
fatigue, anorexia and infections, with serious adverse events including infection, sepsis and 
pyrexia. In the second trial, another multi-institutional single-arm study, a total of 71 
patients were enrolled (Piekarz 2009). The response rate was 34%, with 4 CRs (6%). The 
median duration of response was 13.7 months. The main toxicities included nausea, 
vomiting, fatigue, and transient thrombocytopenia and neutropenia, anemia, and ECG T-
wave changes, with serious adverse events including infection, supraventricular 
arrhythmia, ventricular arrhythmia, edema, pyrexia, nausea, leukopenia and 
thrombocytopenia. There are several other HDAC inhibitors currently in clinical trials as 
single agents, with similar promising results.  
There are several compelling clinical reasons to use these epigenetic modalities in 
combination. As described above (Section 5.3), combining a DNA demethylating agent and 
an HDAC inhibitor appears to improve efficacy. In addition, the combination could 
decrease toxicity. In general, demethylating agents and HDAC inhibitors can cause 
significant toxicity, including grades 3 and 4 myelosuppression. The combination of the 
demethylating agent, decitabine, and the HDAC inhibitor, depsipeptide, was recently 
demonstrated to synergistically inhibit growth of lung and breast cancer cells, at 1000-fold 
lower doses of depsipeptide than what is used clinically (Chen 2010). 
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Clinical trials with demethylating agents and HDAC inhibitors in combination are still in 
the early stages of investigation, in phase I and II trials (Tables 4-6). At this time only eight 
trials have been published (Table 4). In a phase II trial with valproic acid in combination 
with hydralazine in 12 patients with refractory MDS, the CR/PR rate was 16%, with an 
overall RR of 50% (Candelaira 2011) (Table 4). The response rate includes a hematologic 
improvement (HI) rate of 34%, assessed per the International Working Group criteria 
(Cheson 2006). In comparison, a phase II trial with valproic acid in 43 MDS/AML patients 
showed a response in 18 patients (overall RR 24%), with no CR, 1 PR (2%) and 18 HI (22%) 
(Kuendgen 2005). It is important to note that the valproic acid dose in the Candelaira trial 
was fixed at 30 mg/kg/day, while valproic acid dose in the Kuendgen trial was titrated to 
valproic acid serum levels, which is more accurate. Therefore, the patients in the Candelaira 
trial might have been underdosed, and true outcomes in that trial may have been even 
better. However, while it appears that the addition of hydralazine to valproic acid might 
improve response, the study numbers for both trials were low, particularly the Candelaira 
trial (Candelaira 2011), and it would be premature to draw any conclusions about the 
superiority of this combination treatment.  
Decitabine and valproic acid were combined in a phase I/II trial with 54 patients with MDS 
and AML (Garcia-Manero 2006) (Table 4). Six of the patients had MDS, of whom 3 responded 
(CR and PR) (50%). The number of CRs in this group was not reported. The sample size is too 
small to draw any conclusions about the efficacy of adding valproic acid to decitabine. 
Nevertheless, this combination warrants further investigation in an MDS-only population, as 
the response rate in a phase III trial with decitabine alone in 170 MDS patients was only 17% 
(Kantarjian 2006). The remaining 48 patients in the phase I/II trial had AML, among whom 9 
patients experienced a response (19%). The number of CRs among AML patients was not 
reported. In a smaller phase I trial, 11 AML patients were also treated with decitabine and 
valproic acid (Blum 2007). Six patients (55%) responded, with 2 CRs (18%). As a comparison, 
in a phase II trial of decitabine monotherapy, limited to 55 previously-untreated older patients 
(age > 60), the overall response rate was 25%, with a 24% CR rate (Cashen 2010). The 19% RR 
for the AML patients in the phase I/II combination trial (Garcia-Manero 2006) is comparable to 
the 25% RR in the monotherapy trial (Cashen 2010), while the 55% RR observed in the small 
phase I trial (Blum 2007) is impressive. However, the interpretation of the small phase I trial in 
particular is limited by its small sample size (n=11). 
In a study by Soriano et al. (2007), in which 5-azacytidine and valproic acid in combination 
with all-trans retinoic acid (ATRA) were administered to 53 AML and high-risk MDS 
patients, patients had impressive outcomes (Table 4). They had a RR of 42%, and a CR rate 
of 22%. However, another study of 5-azacytidine, valproic acid and ATRA by Raffoux et al. 
(Raffoux 2010) in 65 patients, also with AML and high-risk MDS, showed a markedly lower 
RR of 26%, with a similar CR rate of 21%. It is difficult to determine the reason for the 
discrepancies between these studies in response rates. They may be due to slightly different 
dosing schedules. In comparison to three clinical trials with valproic acid and ATRA in 
older and/or poor-risk patients with AML, with response rates of 11-55% (Pailatrino 2005, 
Bug 2005, Raffoux  2005), it does not appear that adding 5-azacytidine to valproic acid and 
ATRA adds to efficacy. 
In solid tumors, combination therapy has not appeared to be effective. Stathis et al. did not 
observe any responses with decitabine and vorinostat (Stathis 2011) (Table 4). However, it 
was a phase I trial, and most of the 43 patients were not treated with the optimal doses (i.e. 
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recommended phase II doses) of the drugs. Nevertheless, the lack of response is similar to 
the lack of response observed with each individual agent in solid tumors. For example, 
Abele et al. (Abele 1987) observed only 1 response in 82 evaluable patients (1%) with 
advanced solid tumors treated with decitabine. Similarly, in a phase I trial in 73 patients 
with advanced solid tumors treated with oral vorinostat, only 1 CR (1%) and 3 PRs were 
noted (4%) (Kelly 2005). However, in another phase I trial with intravenous vorinostat, 17 
advanced solid tumor patients were enrolled, of whom 4 had a response (23%, all PR) (Kelly 
2003) (Table 4). It is unclear if this response is due to the use of intravenous vorinostat, but 
this method of delivery is no longer in development, and all current trials with vorinostat 
are using the oral form. Candelaria’s 2007 trial with hydralazine, valproic acid and 
chemotherapy in 17 patients with solid tumors looks promising, with a 27% response rate 
(Table 4) (Candelaria 2007). It is especially impressive since valproic acid as monotherapy in 
solid tumors is not effective, as demonstrated in a phase I clinical trial in which none of 18 
evaluable patients had a response (Atmaca 2007). However, it is difficult to assess the effect 
of chemotherapy itself. Since each patient received a different chemotherapy regimen, 
comparisons to historical controls with chemotherapy-only are difficult. In this trial, the 
authors noted that hydralazine and valproic administration permitted a lower 
chemotherapy dose intensity (Candelaria 2007), which might have led to lower rates of 
toxicity. This outcome warrants further clinical trials of chemotherapy administered 
sequentially after epigenetic agents. 
One of the most impressive results with combination therapy appears to be the trial of 
hydralazine and valproic acid with chemotherapy (doxorubicin [Adriamycin]/ 
cyclophosphamide [AC]) as neoadjuvant therapy in 16 patients with locally-advanced breast 
cancer, where the response rate was 81%, with a clinical CR rate of 31% and pathologic CR 
rate of 6.6% (Arce-Salinas 2006) (Table 4). However, these outcomes are similar to those 
observed with AC chemotherapy alone in the neoadjuvant setting, with a response rate of 
75%, clinical CR of 31%, and pathologic CR of 16%, albeit for patients with early breast 
cancer (Smith 2004). Currently, taxanes are often used with anthracyclines as neoadjuvant 
chemotherapy in the locally-advanced setting. The response rates range from 71 to 92%, 
with clinical CR rates from 17 to 31%, and pathologic CR rates 5-26% (Guarneri 2007), which 
are similar to the outcomes of AC with hydralazine and valproic acid (Arce-Salinas 2006), 
with potentially less hematologic toxicity.  
To date, all of the studies with epigenetic agents in combination have been phase I or phase 
II trials, with sub-optimal historical controls with which we can compare response rates. 
Most have demonstrated transient hypomethylation or induction of histone acetylation 
(Table 4). Currently, there are many combination phase I and II trials in progress (Tables 6-
7), using newer and potentially less toxic HDAC inhibitors, or studying the combination in 
non-hematologic malignancies (e.g. lung cancer). However, in order to truly assess the 
utility of combination epigenetic therapy, large, randomized, placebo-controlled phase III 
trials should be performed, directly comparing monotherapy with combination therapy, to 
assess overall survival, the most clinically meaningful endpoint. Furthermore, future clinical 
trial participation should be based on molecular biomarkers to predict which patients would 
respond best to the epigenetic agents. For example, it was demonstrated that a combination 
of a demethylating agent, zebularine, and HDAC inhibitor, depsipeptide, was only effective 
in tumor cells with silenced but not deleted CDKN2A  (Chen 2010). A future clinical trial 
might focus on patients with silenced CDKN2A. 
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